The mechanically expandable LOTUS Valve and LOTUS Edge transcatheter aortic valve systems

References

• Meredith IT, Worthley SG, Whitbourn RJ, et al. Transfemoral aortic valve replacement with the repositionable lotus valve system in high surgical risk patients: the REPRISE I study. EuroIntervention. 2014;9:1264–1270.
   PubMed Web of Science ®Google Scholar
• Bagur R, Choudhury T, Mamas MA. Transcatheter aortic valve implantation with the repositionable and fully retrievable lotus valve system(TM). J Thorac Dis. 2017;9:2798–2803.
   PubMed Web of Science ®Google Scholar
• Meredith IT, Walters DL, Dumonteil N, et al. 1-year outcomes with the fully repositionable and retrievable lotus transcatheter aortic replacement valve in 120 high-risk surgical patients with severe aortic stenosis: results of the REPRISE II study. JACC Cardiovasc Interv. 2016;9:376–384.
   PubMed Web of Science ®Google Scholar
• Meredith IT, Dumonteil N, Blackman DJ, et al. Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients. EuroIntervention. 2017;13:788–795.
   PubMed Web of Science ®Google Scholar
• Falk V, Wohrle J, Hildick-Smith D, et al. Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND study. Eur Heart J. 2017;38:3359–3366.
   PubMed Web of Science ®Google Scholar
• Feldman TE, Reardon MJ, Rajagopal V, et al. Effect of mechanically expanded vs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis: the REPRISE III randomized clinical trial. Jama. 2018;319:27–37.
   PubMed Web of Science ®Google Scholar
• Meredith IT, et al. Three-year outcomes with the fully repositionable and retrievable Lotus Transcatheter Aortic Replacement Valve in 120 high-risk surgical patients with severe aortic stenosis: Results from the REPRISE II CE-Mark study. Presented at: Transcatheter and Cardiovascular Therapeutics 2016, October 31, 2016; Washington, DC, USA.
   Google Scholar
• Hildick-Smith D, et al. Four‐year outcomes with the fully repositionable and retrievable Lotus transcatheter Aortic valve: Results from the REPRISE II study. Presented at: Transcatheter Cardiovascular Therapeutics Congress 2017, Oct 29th-Nov 2nd 2017, Denver, USA.
   Google Scholar
• Van Mieghem NM The RESPOND study at 1 year: primary endpoint outcomes with a repositionable and fully retrievable aortic valve in routine clinical practice. Presented at EuroPCR, May 16–19, 2017; Paris, France.
   Google Scholar
• Hildick-Smith D RESPOND: 2 years clinical outcomes in patients treated with a repositionable and fully retrievable aortic valve in routine clinical practice. Presented at EuroPCR, September 23, 2018; Paris, France.
   Google Scholar
• Asch FM, Vannan MA, Singh S, et al. Hemodynamic and echocardiographic comparison of the lotus and corevalve transcatheter aortic valves in patients with high and extreme surgical risk: an analysis from the REPRISE III randomized controlled trial (repositionable percutaneous replacement of stenotic aortic valve through implantation of lotus valve system - randomized clinical evaluation). Circulation. 2018;137:2557–2567.
   PubMedGoogle Scholar
• Meduri C Impact of pacemaker implantation on clinical outcomes following treatment with a retrievable and fully repositionable Aortic valve: a subanalysis of the REPRISE III randomised controlled clinical trial. Presented at PCR London Valves, September 25 2017; London, UK.
   Google Scholar
• van Gils L, Wohrle J, Hildick-Smith D, et al. Importance of contrast aortography with lotus transcatheter aortic valve replacement: a post hoc analysis from the RESPOND post-market study. JACC Cardiovasc Interv. 2018;11:119–128.
   PubMed Web of Science ®Google Scholar
• Bagur R, Rodes-Cabau J, Gurvitch R, et al. Need for permanent pacemaker as a complication of transcatheter aortic valve implantation and surgical aortic valve replacement in elderly patients with severe aortic stenosis and similar baseline electrocardiographic findings. JACC Cardiovasc Interv. 2012;5:540–551.
   PubMed Web of Science ®Google Scholar
• Dumonteil N, Meredith IT, Blackman DJ, et al. Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort. EuroIntervention. 2017;13:796–803.
   PubMed Web of Science ®Google Scholar
• Van Mieghem N, Blackman DJ, Hildick-Smith D, et al. Transcatheter aortic valve replacement using the lotus valve with depth guard: first report from the RESPOND extension study. Presented at CRT, February 20, 2017; Washington DC, USA.
   Google Scholar
• Herrmann HC, Thourani VH, Kodali SK, et al. One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134:130–140.
   PubMed Web of Science ®Google Scholar
• Thourani VH, Kodali S, Makkar RR, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387:2218–2225.
   PubMed Web of Science ®Google Scholar
• Wendler O, Schymik G, Treede H, et al. SOURCE 3 registry: design and 30-day results of the European postapproval registry of the latest generation of the SAPIEN 3 transcatheter heart valve. Circulation. 2017;135:1123–1132.
   PubMed Web of Science ®Google Scholar
• Meredith IT. First report of two-year outcomes with the repositionable Lotus™ Aortic Valve Replacement System: Results from the REPRISE I Feasibility Study. Presented at Transcatheter and Cardiovascular Therapeutics 2014, September 13, 2014; Washington, DC, USA.
   Google Scholar
• Meredith IT Two-year outcomes with a fully repositionable and retrievable percutaneous aortic valve in 250 high surgical risk patients: results from the REPRISE II trial extended cohort. Presented at PCR London Valves, September 19, 2016; London, UK.
   Google Scholar
• Meredith IT, Worthley SG, Whitbourn RJ, et al. First report of three-year outcomes with the repositionable and fully retrievable lotus aortic valve replacement System: results from the REPRISE I feasibility study. Presented at Transcatheter and Cardiovascular Therapeutics, October 13, 2015; San Francisco, CA, USA.
   Google Scholar
• Meredith IT, Houle V, Walters D, et al. Three-year outcomes with the fully repositionable and retrievable lotus transcatheter aortic replacement valve in 120 high-risk surgical patients with severe aortic stenosis: results from the REPRISE II CE-mark study. Presented at Transcatheter and Cardiovascular Therapeutics, October 31, 2016; Washington, DC, USA.
   Google Scholar
• Meredith IT, Worthley S, Whitbourn R, et al. Four-year clinical outcomes following TAVR with the repositionable and fully retrievable lotus valve system: an update from the REPRISE I study. Presented at Transcatheter and Cardiovascular Therapeutics, October 31, 2016; Washington, DC, USA.
   Google Scholar
• Gooley R, Worthley SG, Whitbourn RJ, et al. Final Results from the REPRISE I study: five-year clinical outcomes with the repositionable and fully retrievable lotus valve system. EuroIntervention. 2018 Sept;25. DOI:10.4244/EIJ-D-18-00664. Epub ahead of print.
   Google Scholar
• Walters D, Gooley R, Raffel OC, et al. First report of clinical outcomes with the next generation lotus valve system: results from the lotus edge feasibility trial. Presented at American College of Cardiologists, March 18 2017; Washington DC, USA.
   Google Scholar
• Urena M, Webb JG, Tamburino C, et al. Permanent pacemaker implantation after transcatheter aortic valve implantation: impact on late clinical outcomes and left ventricular function. Circulation. 2014;129:1233–1243.
   PubMed Web of Science ®Google Scholar
• Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from the U.S. society of thoracic surgeons/American college of cardiology TVT registry. JACC Cardiovasc Interv. 2016;9:2189–2199.
   PubMed Web of Science ®Google Scholar
• Pasic M, Unbehaun A, Buz S, et al. Annular rupture during transcatheter aortic valve replacement: classification, pathophysiology, diagnostics, treatment approaches, and prevention. JACC Cardiovasc Interv. 2015;8:1–9.
   PubMed Web of Science ®Google Scholar
• Breitbart P, Minners J, Pache G, et al. Outcomes in patients with contained ruptures of the aortic annulus after transcatheter aortic valve implantation with balloon-expandable devices. EuroIntervention. 2017;13:1300–1302.
   PubMed Web of Science ®Google Scholar
• Eggebrecht H, Vaquerizo B, Moris C, et al. Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). Eur Heart J. 2018;39:676–684.
   PubMed Web of Science ®Google Scholar
• Bagur R, Teefy PJ, Kiaii B, Diamantouros P, Chu MWA. First North American experience with the transfemoral ACURATE-neo(TM) self-expanding transcatheter aortic bioprosthesis. Catheter Cardiovasc Interv 2017;90:130–138.
   Google Scholar